Research programme: cancer therapies - H3 Biomedicine

Drug Profile

Research programme: cancer therapies - H3 Biomedicine

Alternative Names: H3B 6545; SF3B1 inhibitors - H3 Biomedicine; SF3B1 modulator - H3 Biomedicine; Splicing factor inhibitor - H3 Biomedicine; Splicing inhibitors - H3 Biomedicine

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator H3 Biomedicine
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor alpha modulators; Estrogen receptor antagonists; Phosphoprotein modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Jun 2017 Pharmacodynamics data from a preclinical trial released by H3 Biomedicine
  • 11 Dec 2015 Preclinical trials in Cancer in USA (PO)
  • 28 Jan 2011 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top